This trial is active, not recruiting.

Condition atopic dermatitis
Treatments pimecrolimus cream 1% (valeant), vehicle cream, pimecrolimus cream, 1%
Phase phase 3
Sponsor Actavis Inc.
Start date February 2015
End date July 2016
Trial size 587 participants
Trial identifier NCT02791308, SYM 2014-03


The purpose of this study is to compare the safety and efficacy profiles of Watson Laboratories, Inc.'s Pimecrolimus Cream, 1% to those of Valeant Pharmaceuticals North America LLC's Elidel® (pimecrolimus) Cream, 1%, and to demonstrate the superior efficacy of the two active creams over that of the placebo (Vehicle of test product), in the treatment of mild to moderate atopic dermatitis.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Pimecrolimus Cream, 1% (Actavis)
pimecrolimus cream, 1% Pimecrolimus Cream, 1% (Actavis)
(Active Comparator)
Reference listed drug: Elidel 1% cream (Valeant Pharmaceuticals North America LLC)
pimecrolimus cream 1% (valeant) Elidel® (pimecrolimus) Cream, 1% (Valeant)
(Placebo Comparator)
Cream vehicle of the test product (Actavis)
vehicle cream Vehicle of test product (Actavis)

Primary Outcomes

Proportion of subjects in each treatment group with treatment success, defined as a grade of clear or almost clear (a score of 0 or 1 on the IGA) within all treatment areas at the end of treatment
time frame: 15 days

Eligibility Criteria

Male or female participants from 12 years up to 90 years old.

Inclusion Criteria: - Willing and able to provide written informed consent/assent for the study. - Non-immunocompromised male or female aged 12 years or older. - A clinical diagnosis of mild to moderate atopic dermatitis that has failed to respond adequately to other topical prescription treatments for atopic dermatitis, or subjects for whom the use of those other treatments is deemed inadvisable. - A diagnosis of atopic dermatitis for at least 3 months. - A baseline Investigator's Global Assessment (IGA) of disease severity of mild or moderate (score of 2 or 3). - An affected area of atopic dermatitis involvement of at least 5% of the body surface area (BSA) at Visit 2/Day 1 (Baseline), as defined by the criteria of Hanifin and Rajka (1980). - Treatment with a bland emollient for at least 7 days prior to Visit 2/Day 1 (Baseline). - Agree to adhere to protocol-specified requirements and concomitant therapy restrictions. - Willing to avoid constant sun exposure and the use of tanning booths or other UV light sources during participation in the study. - In general good health, non-immunocompromised, and free from any clinically significant disease, other than atopic dermatitis, that might interfere with the study evaluations. - Willing and able to understand and comply with the requirements of the study, apply the study medication as instructed, return for the required study visits, comply with therapy prohibitions, and complete the study. - Female subjects of childbearing potential (excluding women who are surgically sterilized [hysterectomy, bilateral tubal ligation, or bilateral ovariectomy] or have been postmenopausal for at least 1 year) must have a negative urine pregnancy test and must be willing to use a medically accepted method of contraception during the study. The following are considered acceptable methods of birth control for the purpose of this study: oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier methods (e.g., condom and spermicide), contraceptive injection (Depo-Provera®), intrauterine device (IUD), hormonal IUD (Mirena®), Essure® permanent birth control, and abstinence with a documented second acceptable method of birth control if the subject becomes sexually active. Subjects entering the study who are on hormonal contraceptives must have been on the method for at least 90 days prior to the study and continue the method for the duration of the study. Subjects who had used hormonal contraception and stopped must have stopped no less than 90 days prior to Visit 1. Exclusion Criteria:

Additional Information

Official title Double-Blind Randomized Vehicle Controlled Study Evaluating Safety and Bioequivalence of Generic Pimecrolimus Cream 1% and Elidel® Comparing Both Active Treatments to a Vehicle Control in Treatment of Mild to Moderate Atopic Dermatitis
Description Pimecrolimus cream, 1% is a calcineurin inhibitor immunosuppressant. Pimecrolimus inhibits T cell activation by blocking the transcription of early cytokines. Pimecrolimus cream, 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. This study is being conducted to evaluate the clinical bioequivalence of sponsor's formulation of Pimecrolimus Cream, 1%, the Test product, and Elidel Cream, 1%, the Reference product. A vehicle control arm is included to demonstrate that the Test and Reference products are active and to establish that the study is sufficiently sensitive to detect differences between products.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Actavis Inc..